恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗

摩熵医药01-12

1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。此次申请的适应症为治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者，为PNH患者带来了新的治疗选择。截图来源：企业公告富马酸立康可泮胶囊是恒瑞医药自主研发的1类新药，其独特之处在于它是一款以补体活化系统旁路途径中的B因子（CFB）为靶点的口服小分子抑制剂。补体B...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603221745?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-12 16:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2603221745","market":"hk","top_or_hot":-1,"title":"恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗","media":"摩熵医药","content":"<div>\n<p>1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。此次申请的适应症为治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者，为PNH患者带来了新的治疗选择。截图来源：企业公告富马酸立康可泮胶囊是恒瑞医药自主研发的1类新药，其独特之处在于它是一款以补体活化系统旁路途径中的B因子（CFB）为靶点的口服小分子抑制剂。补体B...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药1类新药“富马酸立康可泮胶囊”上市申请获受理，靶向补体B因子助力PNH治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 16:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b><strong>摩熵医药</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。此次申请的适应症为治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者，为PNH患者带来了新的治疗选择。截图来源：企业公告富马酸立康可泮胶囊是恒瑞医药自主研发的1类新药，其独特之处在于它是一款以补体活化系统旁路途径中的B因子（CFB）为靶点的口服小分子抑制剂。补体B...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0359201612.USD","symbol_name":"贝莱德中国基金A2","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b","article_id":"2603221745","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112171020a4b9ece8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603221745","pubTimestamp":1768206326,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。该试验旨在评价富马酸立康可泮胶囊在既往未接受过补体抑制剂治疗的PNH患者中的有效性和安全性。图源：摩熵医药-全球药物研发数据库研究结果表明，富马酸立康可泮胶囊在提高PNH患者的血红蛋白水平、避免输血需求以及改善患者疲劳症状等方面均表现出优于C5补体抑制剂的疗效。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0359201612.USD":"贝莱德中国基金A2","BK1191":"制药","01276":"恒瑞医药","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC"},"translate_title":"Hengrui Medicine's Class 1 new drug \"Likangkopan Fumarate Capsules\" marketing application was accepted, targeting complement B factor to assist PNH treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1.5},"content_text":"1月9日，恒瑞医药对外发布公告称，其自主研发的1类新药——富马酸立康可泮胶囊的药品上市许可申请已正式获得受理。此次申请的适应症为治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者，为PNH患者带来了新的治疗选择。截图来源：企业公告富马酸立康可泮胶囊是恒瑞医药自主研发的1类新药，其独特之处在于它是一款以补体活化系统旁路途径中的B因子（CFB）为靶点的口服小分子抑制剂。补体B因子抑制剂通过靶向因子B来抑制替代途径（AP），能够同时控制血管内溶血和血管外溶血，从而有效弥补了C5补体抑制剂在治疗上的不足。此外，该药物采用口服给药方式，大大提高了患者的用药依从性。查数据，找摩熵！图源：摩熵医药数据库-全球药物研发数据库目前，富马酸立康可泮胶囊用于IgA肾病患者的临床研究也正在紧锣密鼓地进行中。值得一提的是，在2025年11月，该药物已被国家药品监督管理局药品审评中心（CDE）纳入优先审评程序，这标志着其研发进程和重要性得到了监管机构的认可。查数据，找摩熵！图源：摩熵医药-全球药物研发数据库此次富马酸立康可泮胶囊的申报上市，是基于一项关键性的多中心、随机、开放、阳性对照III期临床试验。该试验旨在评价富马酸立康可泮胶囊（研发代号：HRS-5965）在既往未接受过补体抑制剂治疗的PNH患者中的有效性和安全性。主要研究者：该研究由中国医学科学院血液病医院的张凤奎教授和中国医学科学院北京协和医院的韩冰教授共同担任主要研究者，确保了研究的科学性和权威性。参与中心：全国共有13家知名医疗中心参与了此项研究，体现了研究的广泛性和代表性。主要终点：研究设定了血红蛋白水平≥12g/dL的受试者比例作为主要终点，以准确评估药物的治疗效果。查数据，找摩熵！图源：摩熵医药-全球药物研发数据库研究结果表明，富马酸立康可泮胶囊在提高PNH患者的血红蛋白水平、避免输血需求以及改善患者疲劳症状等方面均表现出优于C5补体抑制剂的疗效。这一发现为PNH患者提供了更为有效和便捷的治疗方案，有望显著改善患者的生活质量。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603221745","isCrawlerRequest":true}